Blueprint Medicines Corp Cash Flow Conversion Efficiency
Blueprint Medicines Corp cash flow conversion efficiency. Based on the latest financial reports, Blueprint Medicines Corp (BPMC) has a cash flow conversion efficiency ratio of -0.159x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-54.48 Million) by net assets ($342.13 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Blueprint Medicines Corp (2013–2024)
Cash flow conversion efficiency of Blueprint Medicines Corp from 2013 to 2024. This chart illustrates how Blueprint Medicines Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Blueprint Medicines Corp (BPMC) stock price for real-time trading data and today's change.
Blueprint Medicines Corp Cash Flow Conversion Ratio Explained
Blueprint Medicines Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Blueprint Medicines Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Blueprint Medicines Corp ranked by their cash flow conversion efficiency. Also see BPMC market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TG Therapeutics Inc
NASDAQ:TGTX
|
0.035x |
|
CAE Inc.
TO:CAE
|
0.038x |
|
Datang International Power Generation Co Ltd Class A
SHG:601991
|
0.082x |
|
Quinenco
SN:QUINENCO
|
0.028x |
|
Restaurant Brands International Limited Partnership
TO:QSP-UN
|
0.043x |
|
Bid Corporation Ltd
JSE:BID
|
0.182x |
|
Element Solutions Inc
NYSE:ESI
|
0.033x |
|
Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR
|
0.041x |
Annual Cash Flow Conversion Efficiency for Blueprint Medicines Corp (2013–2024)
The table below shows the annual cash flow conversion efficiency of Blueprint Medicines Corp from 2013 to 2024. Review Blueprint Medicines Corp (BPMC) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $298.67 Million | $-192.59 Million | -0.645x | +80.72% |
| 2023-12-31 | $130.61 Million | $-436.85 Million | -3.345x | -242.73% |
| 2022-12-31 | $514.68 Million | $-502.28 Million | -0.976x | -217.21% |
| 2021-12-31 | $970.74 Million | $-298.65 Million | -0.308x | -216.86% |
| 2020-12-31 | $1.47 Billion | $387.04 Million | 0.263x | +143.97% |
| 2019-12-31 | $464.36 Million | $-278.01 Million | -0.599x | -43.34% |
| 2018-12-31 | $419.01 Million | $-175.01 Million | -0.418x | -117.42% |
| 2017-12-31 | $623.97 Million | $-119.86 Million | -0.192x | -66.98% |
| 2016-12-31 | $213.08 Million | $-24.51 Million | -0.115x | +47.71% |
| 2015-12-31 | $143.98 Million | $-31.68 Million | -0.220x | +77.98% |
| 2014-12-31 | $35.43 Million | $-35.40 Million | -0.999x | -107.86% |
| 2013-12-31 | $-1.50 Million | $-19.02 Million | 12.717x | -- |
About Blueprint Medicines Corp
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast … Read more